We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

113 hedge funds and large institutions have $264M invested in CytomX Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

856% more call options, than puts

Call options by funds: $86K | Put options by funds: $9K

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

18% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 33

4% more funds holding

Funds holding: 109 → 113 (+4)

0.25% more ownership

Funds ownership: 78.67% → 78.92% (+0.25%)

34% less capital invested

Capital invested by funds: $400M → $264M (-$135M)

Holders
113
Holders Change
+4
Holders Change %
+3.67%
% of All Funds
2.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
39
Reduced
33
Closed
16
Calls
$86K
Puts
$9K
Net Calls
+$77K
Net Calls Change
+$77K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.67M
2
Victory Capital Management
Victory Capital Management
Texas
+$6.28M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.29M
4
Prudential Financial
Prudential Financial
New Jersey
+$2.22M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$1.92M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.88M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.33M
3
Millennium Management
Millennium Management
New York
-$4.06M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.71M
5
Morgan Stanley
Morgan Stanley
New York
-$3.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Massachusetts Financial Services
26
Massachusetts Financial Services
Massachusetts
$1.44M +$1.92M +194,862 New
BBA
27
Baker Bros. Advisors
New York
$1.44M – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.43M +$111K +11,293 +6%
CPC
29
Congress Park Capital
New York
$1.24M -$7.89K -800 -0.5%
GIM
30
Granahan Investment Management
Massachusetts
$1.13M +$60.9K +6,174 +4%
AllianceBernstein
31
AllianceBernstein
Tennessee
$1.08M -$211K -21,350 -13%
Allianz Asset Management
32
Allianz Asset Management
Germany
$1.06M -$375K -38,002 -21%
PAG
33
Private Advisor Group
New Jersey
$991K -$49.3K -5,000 -3%
JP Morgan Chase
34
JP Morgan Chase
New York
$991K +$68.7K +6,969 +5%
American Century Companies
35
American Century Companies
Missouri
$905K +$1.21M +122,572 New
MCM
36
Moore Capital Management
New York
$738K -$247K -25,000 -20%
DCM
37
DAFNA Capital Management
California
$738K +$986K +100,000 New
Acadian Asset Management
38
Acadian Asset Management
Massachusetts
$691K -$554K -56,209 -38%
PP
39
PDT Partners
New York
$664K +$888K +90,037 New
CS
40
Credit Suisse
Switzerland
$661K +$528K +53,478 +148%
UBS Group
41
UBS Group
Switzerland
$658K +$645K +65,403 +274%
WCM
42
Weld Capital Management
New York
$637K +$699K +70,880 +458%
Swiss National Bank
43
Swiss National Bank
Switzerland
$619K – – –
Jacobs Levy Equity Management
44
Jacobs Levy Equity Management
New Jersey
$617K +$104K +10,500 +14%
HP
45
Harbourvest Partners
Massachusetts
$584K – – –
OAM
46
Oxford Asset Management
United Kingdom
$578K +$772K +78,283 New
GCP
47
GSA Capital Partners
United Kingdom
$576K +$121K +12,302 +19%
Two Sigma Investments
48
Two Sigma Investments
New York
$563K -$573K -58,126 -43%
Assenagon Asset Management
49
Assenagon Asset Management
Luxembourg
$560K -$478K -48,500 -39%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$527K +$2.12K +215 +0.3%
1
2
3 4 5

CTMX Hedge Fund Activity: Q3 2019 in Review

113 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2019, worth a combined $264M — down 34% from $400M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CTMX positions and 16 closed out — a net gain of 4 holders — while 39 added to existing stakes and 33 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $8.67M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.88M.

  • 113 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2019, up from 109 in Q2 2019.
  • Funds reported $264M of CytomX Therapeutics stock for Q3 2019, down 34% quarter-over-quarter.
  • 20 funds opened new CytomX Therapeutics positions in Q3 2019 and 16 closed out, a net change of +4 holders.
  • The largest CytomX Therapeutics buyer in Q3 2019 was Wellington Management Group, an estimated $8.67M added.
  • The largest CytomX Therapeutics seller in Q3 2019 was T. Rowe Price Associates, an estimated $5.88M sold.

Based on aggregated 13F filings for Q3 2019.